Silence announced today that it will only initiate the zerlasiran Phase 3 CVOT study once a partner is secured. Following this announcement, Silence is extending its projected cash runway into 2027. The Company plans to prioritize development of divesiran in PV and programs in rare conditions with high unmet needs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLN:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Sell Rating on Silence Therapeutics Due to Suboptimal Dosing, Financial Constraints, and Competitive Lag
- Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
- Silence Therapeutics initiated with a Sell at Goldman Sachs
- Silence management enthusiastic ahead of catalysts, says H.C. Wainwright